Initiation of first-line antiretroviral treatment with TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the first clinical contact in France: Trial IMEA 055 – FAST - FAST

IMEA0 个研究点目标入组 110 人开始时间: 2019年2月19日最近更新: 2019年12月10日

适应症

试验速览

暂无简介。

•-age > 18 years
•-newly diagnosed HIV-infected individual evidenced by any of the following tests: (i) positive self-test, (ii) positive HIV Rapid antibody test, (iii) positive HIV immunoassay (ELISA 4th generation) test
•-antiretroviral-treatment naive
•-negative urine pregnancy test for women of childbearing potential and willing to use effective contraception (mechanical or medicamental)
•-willing to sign an informed written consent–
•-regular health insurance
•-willing to provide two distinct contact information (telephone number and/or email) in order to be easily reached if needed between Day 0 and Day 7
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 110
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

•-clinical symptoms suggestive of opportunistic infections
•-participant not willing to provide two distinct contact information
•-a woman who is pregnant or breast-feeding or planning to become pregnant during the expected study period.
•-Co-medication with deleterious interaction with study treatment (eg enzyme inducer)

发起方

IMEA